- Home
- REFI vs XOMA Comparison
REFI vs XOMA Comparison
Compare REFI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | XOMA |
|---|---|---|
| Founded | 2021 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 326.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | XOMA |
|---|---|---|
| Price | $12.11 | $24.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $20.00 | ★ $63.25 |
| AVG Volume (30 Days) | 115.1K | ★ 737.4K |
| Earning Date | 03-11-2026 | 03-16-2026 |
| Dividend Yield | ★ 16.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | 0.82 |
| Revenue | ★ $54,287,847.00 | $47,106,000.00 |
| Revenue This Year | $13.69 | $77.29 |
| Revenue Next Year | $3.55 | $29.30 |
| P/E Ratio | ★ $7.34 | $32.75 |
| Revenue Growth | N/A | ★ 118.02 |
| 52 Week Low | $11.85 | $18.35 |
| 52 Week High | $16.27 | $39.92 |
Technical Indicators
Market Signals| Indicator | REFI | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 41.23 |
| Support Level | $12.15 | $24.14 |
| Resistance Level | $12.49 | $27.87 |
| Average True Range (ATR) | 0.24 | 1.70 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 9.72 | 11.65 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.